Azitra, Inc.

AZTR Healthcare Biotechnology

Azitra, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7,500.00, down 98.9% from fiscal 2023. In the quarter to June 2026, EPS grew 85.6% and free cash flow fell 19.6%, each against the same quarter a year earlier.

0.07 0.00 0.00%
Market cap
$4.3M
P/E
1.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
3/9
Altman Z
−14.66
Beneish M
13.02
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Piotroski F-Score
— 3 3 — —
P/E ratio
— 0.00 0.00 0.00 0.00
P/S ratio
— 2.80 10.56 14.28 14.28
Altman Z-Score
— (14.66) (16.02) — —
Altman Z″-Score (non-manufacturers)
— (28.50) (38.17) (24.96) (16.73)
P/FCF ratio
— 0.00 0.00 0.00 0.00
Beneish M-Score
— 13.02 (5.04) (2.16) —
P/Operating CF
— (0.63) (2.85) (4.01) (4.01)
P/B ratio
— 0.28 2.49 0.00 0.00
EV/Sales
— (5.04) 7.98 28.82 28.82
EV/EBITDA
— 0.29 0.00 0.00 0.00
EV/FCF
— 0.28 (0.71) (1.05) (1.05)
Current Ratio
2.83 3.80 1.58 1.86 7.02
Net Debt/EBITDA
0.20 0.45 0.27 (0.34) (2.92)
Debt/Equity
0.00 0.00 0.01 (0.18) (1.35)
ROE
(230.65%) (208.27%) 75.80% 43.37% 0.00%
ROA
(176.93%) (143.78%) (205.80%) (154.87%) 0.00%
ROIC
(395.49%) (595.10%) (407.29%) 0.00% 0.00%
Return on Tangible Assets
(438.23%) (198.99%) (769.50%) (487.14%) (142.34%)
Average Days of Receivables
0.00 4,959.13 118.92 342.12 1,108.94
Earnings Yield
— (552.83%) (155.63%) (129.73%) (129.73%)
Free Cash Flow Yield
— (651.14%) (106.01%) (192.37%) (192.37%)
Free Cash Flow per Share
(2.34) (18.49) (222.63) (1,638.92) (0.67)
Book value per Share
0.78 9.98 84.44 (6,841.57) (2.13)
Free Cash Flow
(11.41) (10.56) (7.68) (8.69) (8.07)
EV/EBIT
— 0.27 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates